Company Name | 台灣田邊製藥 |
---|---|
Protocol Number | TNCANA420173 |
Title of Study | An open-label study to evaluate clinical efficacy and safety of canagliflozin in the treatment of type 2 diabetes uncontrolled with insulin therapy |
Primary Objective | The objective of this study is to investigate the efficacy and safety of canagliflozin in patients with type 2 diabetes uncontrolled with insulin therapy. Evaluation of efficacy endpoints will be performed during and after 12 weeks of treatment, and safety evaluation will be performed throughout the entire study period. |
Number of Sites | 1 |
Period of Study | From:2018/04/12 to:2020/04/29 |
Number of Patients | 30-50人 |
IRB Approval Date | 高雄榮民總醫院: 12/06/2017 |
Publication Plan / Date | Unknown/未知 |